ArticleClinical journal of the American Society of Nephrology : CJASN2020
Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Endothelin: A Potential Universal Systemic Biomarker.Current medicinal chemistry · 2026Review
- Article
- Association between Visit-to-Visit Ultrafiltration Volume Variability, Vascular Biomarkers and Cardiovascular Parameters in Chronic Hemodialysis Patients.Journal of clinical medicine · 2024Article
- The Relationship between Vascular Biomarkers (Serum Endocan and Endothelin-1), NT-proBNP, and Renal Function in Chronic Kidney Disease, IgA Nephropathy: A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- Endothelin-1, Extracellular Volume Overload, and Hemodynamics in Hemodialysis Patients.American journal of hypertension · 2024Article
- Endothelial Dysfunction Biomarkers and CKD Incidence in the REGARDS Cohort.Kidney international reports · 2024Article
- The Complex Immunological Alterations in Patients with Type 2 Diabetes Mellitus on Hemodialysis.Journal of clinical medicine · 2024Review
- Evaluation of endothelial glycocalyx injury biomarkers in feline hemotropic mycoplasmosis.Scientific reports · 2024Article
- The Association of Endothelin-1 with Early and Long-Term Mortality in COVID-19.Journal of personalized medicine · 2023Article
- Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently with decline in kidney function.British journal of clinical pharmacology · 2022Article
- Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice.Canadian journal of physiology and pharmacology · 2022Article
- Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin.Journal of clinical medicine · 2022Review
- Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study.BMC nephrology · 2022Article
- Protective effect and mechanism of Shenkang injection on adenine-induced chronic renal failure in rats.Acta cirurgica brasileira · 2022Article
- Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study.Vascular health and risk management · 2022Article
- Endothelin-1 and Parameters of Systolic Blood Pressure in Hemodialysis.American journal of hypertension · 2021Article
- Gut dysbiosis and mortality in hemodialysis patients.NPJ biofilms and microbiomes · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
objectivesEndothelin-1 is a potent endothelium-derived vasoconstrictor peptide implicated in the pathogenesis of hypertension, congestive heart failure, and inflammation, all of which are critical pathophysiologic features of CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: To test the hypothesis that plasma endothelin-1 levels are associated with increased risks of mortality and hospitalization in patients with chronic kidney failure, we measured plasma endothelin-1 levels in a prospective cohort of 794 individuals receiving maintenance hemodialysis. The primary outcomes were time to death and time to hospitalization.
resultsThe median plasma endothelin-1 level was 2.02 (interquartile range, 1.57-2.71) pg/ml. During a median follow-up period of 28 (interquartile range, 21-29) months, 253 individuals (32%) died and 643 individuals (81%) were hospitalized at least once. In multivariable models adjusted for demographic, clinical, and laboratory variables, individuals in the highest quartile of plasma endothelin-1 had a 2.44-fold higher risk of death (hazard ratio, 2.44; 95% confidence interval, 1.61 to 3.70) and a 1.54-fold higher risk of hospitalization (hazard ratio, 1.54; 95% confidence interval, 1.19 to 1.99) compared with individuals in the lowest quartile. The Harrell
conclusionsHigher plasma endothelin-1 is associated with adverse clinical events in patients receiving hemodialysis independent of previously described risk factors. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_05_15_CJN11130919.mp3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.